Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Engineered Cas13 variants with minimal collateral RNA targeting

The application of CRISPR–Cas13 for targeted RNA degradation is hindered by the existence of collateral effects induced by Cas13. We screened hundreds of engineered Cas13 variants using a convenient and sensitive reporter system and obtained several variants with markedly reduced collateral activity and efficient on-target activity, suitable for in vivo applications.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Engineering and characterization of hfCas13d.

References

  1. Smargon, A. A., Shi, Y. J. & Yeo, G. W. RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering. Nat. Cell Biol. 22, 143–150 (2020). A Review article that presents progress in the RNA-targeting CRISPR–Cas field, including the applications of Cas13 for RNA biology.

    Article  CAS  Google Scholar 

  2. Zhang, C. et al. Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d. Cell 175, 212–223.e217 (2018). This paper reports the molecular and structural basis for Cas13d function, including both guide and target RNA recognition.

    Article  CAS  Google Scholar 

  3. Slaymaker, I. M. et al. High-resolution structure of Cas13b and biochemical characterization of RNA targeting and cleavage. Cell Rep. 26, 3741–3751.e3745 (2019). This paper reports a high-resolution structure of Cas13b and demonstrates that Cas13b can be rationally engineered to change RNA cleavage specificity.

    Article  CAS  Google Scholar 

  4. Wang, Q. et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv. Sci. (Weinh.) 6, 1901299 (2019). This paper reports collateral effects of the CRISPR–Cas13a system in eukaryotes for the first time and demonstrates the powerful tumor-eliminating potential of this system.

    CAS  Google Scholar 

  5. Ai, Y., Liang, D. & Wilusz, J. E. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 50, e65 (2022). This paper reports that Cas13d and Cas13b have differing extents of off-target effects and highlights the need for caution when using Cas13 effectors in eukaryotic cells.

    Article  CAS  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01419-7 (2022).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Engineered Cas13 variants with minimal collateral RNA targeting. Nat Biotechnol 41, 29–30 (2023). https://doi.org/10.1038/s41587-022-01423-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01423-x

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research